Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Non-Small Cell Lung Cancer Clinical Trials

A listing of Non-Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (32) clinical trials

People with metastatic non-small cell lung cancer are asked to participate in a research study being conducted by Montefiore Medical Center.  

Phase N/A

KN046 in Patients With Advanced Non-small Cell Lung Cancer

This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.

Phase

Study of INBRX-105 in Patients With Solid Tumors Hodgkin or Non-Hodgkin Lymphoma

This is a first-in-human, open-label, nonrandomized, two-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 ...

Phase

MRx0518 and Pembrolizumab Combination Study

This is a single center, open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma). Subjects will be treated with IV pembrolizumab every 3 weeks and 1 capsule twice daily ...

Phase

Effect of Two Different Preoperative Training Densities in Patients With Non-small-cell Lung Cancer Before Lung Resection Surgery

Pulmonary resection surgery is currently the recommended curative treatment for early stages of non-small cell lung cancer. The implementation of preoperative respiratory rehabilitation programs has shown beneficial results on pulmonary function, functional level, cardiorespiratory conditioning and the occurrence and severity of postoperative complications in this population of patients. Despite these ...

Phase N/A

A Study of XmAb 23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.

Phase

TPST-1120 as Monotherapy and in Combination With (Nivolumab Docetaxel or Cetuximab) in Subjects With Advanced Cancers

This is a phase 1/1b open label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of TPST-1120, a small molecule selective antagonist of PPAR (peroxisome proliferator activated receptor alpha) in adult subjects with selected advanced solid tumors. TPST will be ...

Phase

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

This study has been designed to evaluate the safety of pembrolizumab in participants in India with unresectable or metastatic melanoma and participants with non-small cell lung cancer (NSCLC) who are either untreated (programmed cell death ligand 1 [PD-L1] 50%) or have experienced disease progression after a platinum-containing systemic therapy (PD-L1 ...

Phase

Durvalumab Tremelimumab and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD). (Dose-escalation phase) II. To estimate the progression free survival in patients with previously treated non-small cell lung cancer (NSCLC) treated with durvalumab and tremelimumab in combination with selumetinib in either an intermittent or continuous schedule and compare to historical controls. ...

Phase

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

PRIMARY OBJECTIVES: I. To develop and validate a clinical risk prediction model using clinical factors for the development of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens. SECONDARY OBJECTIVES: I. To examine patient-reported outcomes (PROs) and objective measures of chemotherapy induced peripheral neuropathy (CIPN) to better define the phenotype of ...

Phase N/A